Selegiline Transdermal System In the Treatment of Major Depressive Disorder

@article{Frampton2012SelegilineTS,
  title={Selegiline Transdermal System In the Treatment of Major Depressive Disorder},
  author={J. Frampton and G. Plosker},
  journal={Drugs},
  year={2012},
  volume={67},
  pages={257-265}
}
  • J. Frampton, G. Plosker
  • Published 2012
  • Medicine
  • Drugs
    • Abstract▴ The monamine oxidase (MAO) inhibitor selegiline is selective for MAO-B at the low oral dosages used in the treatment of Parkinson’s disease. However, MAO-A is also inhibited at the high oral dosages needed to effectively treat depression (not an approved indication), necessitating a tyramine-restricted diet. The selegiline transdermal system was designed to deliver antidepressant drug concentrations to the CNS, without substantially impairing small intestine MAO-A activity. At the… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    18 Citations
    Background Citations
    6
    Methods Citations
    2
    18 Citations
    Citation Type

    Citation Type

    Selegiline Transdermal System: In the Treatment of Major Depressive Disorder
    MAO-inhibitors in Parkinson's Disease
    • 140
    • PDF
    The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
    • 12
    • PDF
    Effects of combined treatment with clorgyline and selegiline on extracellular noradrenaline and serotonin levels
    Interaction between Warfarin and Transdermal Selegiline: First Case Report and Literature Review
    Original Article Interaction Between Warfarin and Transdermal Selegiline: First Case Report and Literature Review
    3-Coumaranone derivatives as inhibitors of monoamine oxidase
    • 6
    • PDF
    Structure‐Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases
    • Riri Shi, Q. Wu, +8 authors W. Huang
    • Chemistry, Medicine
    • Chembiochem : a European journal of chemical biology
    • 2019
    • 6
    Monoamine oxidase inhibitors and neuroprotection: a review.
    • 34
    Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease
    • 11

    References

    SHOWING 1-10 OF 27 REFERENCES
    Selegiline Transdermal System in the Prevention of Relapse of Major Depressive Disorder: A 52-Week, Double-blind, Placebo-Substitution, Parallel-Group Clinical Trial
    • 53
    Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors
    • 43
    Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    • 82
    Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    • M. Thase
    • Psychology, Medicine
    • The Journal of clinical psychiatry
    • 2006
    • 6
    • PDF
    A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    • J. Amsterdam
    • Psychology, Medicine
    • The Journal of clinical psychiatry
    • 2003
    • 115
    • PDF
    Oral Versus Transdermal Selegiline: Antidepressant-Like Activity in Rats
    • 34
    Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    • 133
    Monoamine oxidase inhibitors: a new generation.
    • 45
    Why the Transdermal Delivery of Selegiline (6 Mg/24 Hr) Obviates the Need for a Dietary Restriction on Tyramine
    • 11
    Selegiline transdermal system Somerset.
    • I. Mahmood
    • Medicine
    • Current opinion in investigational drugs
    • 2002
    • 6